GLP-1 Receptor Agonists Show Promise for Alcohol Use Disorder Treatment by Modulating Brain Reward Pathways

Alcohol Use Disorder (AUD) remains a critical global public health challenge, yet current pharmacological treatments are limited in number and often lack sufficient efficacy. This creates an urgent need for novel therapeutic strategies. Glucagon-like peptide-1 (GLP-1), an endogenous gut-brain peptide, and its receptor agonists (GLP-1RAs) are gaining significant attention. Beyond their established roles in metabolic regulation, GLP-1RAs influence brain regions associated with reward and reinforcement, such as the nucleus accumbens (NAc) and ventral tegmental area (VTA), which are central to addiction pathology. This review explores the potential of GLP-1RAs to address the unmet needs in AUD treatment by targeting these neural circuits.

This comprehensive review systematically analyzed existing literature on GLP-1 receptor agonists (GLP-1RAs) as potential pharmacological treatments for Alcohol Use Disorder (AUD). The authors focused on the mechanisms of GLP-1 action in the central nervous system, particularly its influence on reward and reinforcement pathways implicated in addiction. The review synthesized findings from preclinical studies and emerging clinical observations to evaluate the therapeutic potential and current understanding of GLP-1RAs in mitigating alcohol-seeking behaviors and consumption. The scope included the endogenous production and degradation of GLP-1, its receptor binding, and the widespread projections of GLP-1 neurons throughout the brain.

The review highlights that GLP-1 is endogenously produced by specific neurons within the nucleus tractus solitarius (NTS), with widespread projections to reward-related regions such as the nucleus accumbens (NAc) and ventral tegmental area (VTA). Activation of the GLP-1 receptor (GLP-1R) in these areas has been shown to modulate dopamine release and reduce the rewarding effects of alcohol. Preclinical studies consistently demonstrate that GLP-1RAs can significantly decrease alcohol intake and preference, as well as reduce relapse-like behaviors in various animal models of AUD. For instance, studies have reported reductions in alcohol consumption ranging from 20% to 60% in rodents treated with GLP-1RAs. The review also notes that GLP-1 has a very short half-life, merely a few minutes, due to rapid degradation by the ubiquitous serum enzyme dipeptidyl peptidase IV (DPP-4) to low-affinity ligands. The truncated forms, particularly GLP-1 (7-36) amide, are the dominant active forms in humans. This rapid degradation necessitates the development of longer-acting analogues for clinical utility. The evidence strongly suggests that GLP-1RAs interfere with the mesolimbic dopamine system, thereby attenuating alcohol's reinforcing properties and potentially offering a novel therapeutic strategy for AUD.